-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Expand the immunotherapy pipeline to provide a new treatment plan for a series of autoimmune diseases
Expand the immunotherapy pipeline to provide a new treatment plan for a series of autoimmune diseasesHangzhou, China and Dipenbeck, Belgium (August 18, 2021): Biomax Biotech (Hangzhou) Co.
Apitope uses its unique technology platform to develop new antigen-specific immunotherapies for a variety of autoimmune diseases
"The Apitope assets we are going to acquire have a good overlap and synergy with our business in the field of allergy immunotherapy, which is very in line with Worg's business strategy
Dr.
Apitope Chairman Stéphane Verdood and CEO Hayley French commented: “We are very pleased to work with Worg to promote the further development of Apitope immunotherapy and provide patients with novel, safe and effective treatments
About Baiming Xinkang
About Baiming XinkangWorg is a professional biopharmaceutical company focusing on the research and development of innovative immunotherapies, striving to meet medical needs in the field of allergies and related diseases
About Apitope
About ApitopeApitope is a clinical stage biotechnology company focusing on the development of antigen-specific immunotherapies for autoimmune diseases